1. Name Of The Medicinal Product
Kamillosan Chamomile Ointment
2. Qualitative And Quantitative Composition
Each tube or sachet of Kamillosan Ointment contains 10.5% extracts of chamomile standardised to give 0.01% L- α-bisabolol active ingredient.
3. Pharmaceutical Form
Light brown ointment with Characteristic odour.
4. Clinical Particulars
4.1 Therapeutic Indications
For prophylaxis and treatment of uncomplicated inflammation of the skin including sore nipples, nappy chafe, nappy rash and chapped hands.
4.2 Posology And Method Of Administration
Kamillosan ointment is for topical application as follows:
Sore nipples in nursing mothers: after breast feeding.
Nappy chafe and nappy rash: at change of nappy.
Other conditions: twice daily as necessary.
4.3 Contraindications
None known
4.4 Special Warnings And Precautions For Use
None known
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
None known
4.6 Pregnancy And Lactation
Kamillosan may be used during pregnancy and lactation.
4.7 Effects On Ability To Drive And Use Machines
None.
4.8 Undesirable Effects
None known.
4.9 Overdose
There are no known symptoms of overdosage.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
The chamomile extract possesses topical anti-inflammatory properties due to the presence of the natural anti-inflammatory substance £-α-bisabolol.
5.2 Pharmacokinetic Properties
Not applicable
5.3 Preclinical Safety Data
There is none applicable
6. Pharmaceutical Particulars
6.1 List Of Excipients
Beeswax BP, Emulsifying wax BP, anhydrous lanolin BP, yellow soft paraffin BP, maize oil and mixed esters of p-hydroxybenzoic acid (preservative)
6.2 Incompatibilities
None known
6.3 Shelf Life
2 years
6.4 Special Precautions For Storage
Store in a dry place below 25oC.
6.5 Nature And Contents Of Container
Aluminium tubes containing 5, 20, 24, 30, 50, 100 and 125g of ointment.
Sachets containing 1 and 1.5g of ointment
6.6 Special Precautions For Disposal And Other Handling
None.
7. Marketing Authorisation Holder
Goldshield Pharmaceuticals ltd.
NLA Tower
12-16 Addiscombe Road
Croydon
Surrey
CR0 0XT
United Kingdom
8. Marketing Authorisation Number(S)
PL 12762/0039
9. Date Of First Authorisation/Renewal Of The Authorisation
01ST October 1999
10. Date Of Revision Of The Text
December 2009
No comments:
Post a Comment